This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Alnylam to Pursue Full Approval & Rolling NDA for Givosiran
by Zacks Equity Research
Alnylam (ALNY) plans to pursue a full approval of givosiran and submit rolling new drug application (NDA) for the same.
Roche Announces Positive Data on Breast Cancer Drug Kadcyla
by Zacks Equity Research
Roche's (RHHBY) breast cancer drug Kadcyla, in a late-stage study in patients suffering from HER2-positive eBCmet, met its goal.
Pharma Stock Roundup: ABBV, NVS' Humira Biosimilar Agreement, BMY's New Cancer Deal
by Zacks Equity Research
AbbVie (ABBV) signs licensing deal with Sandoz, the generic arm of Novartis. J&J (JNJ) gains FDA approval for label expansion of its blood thinner, Xarelto.
3 Large-Cap Pharma Stocks Performing Better Than Industry
by Zacks Equity Research
We focus on three large-cap pharma stocks that are outperforming the industry on the back of their diverse portfolio.
AbbVie Settles With Novartis to Delay Humira Biosimilar in US
by Zacks Equity Research
AbbVie (ABBV) strikes a deal with Sandoz, the generic arm of Novartis, to launch its biosimilar Humira in the United States on Sep 30, 2023.
Teva Gets FDA Committee Nod for Rituxan Biosimilar Filing
by Zacks Equity Research
Teva (TEVA) and partner Celltrion gets unanimous vote from an FDA advisory committee recommending approval of CT-P10, their proposed biosimilar to Roche's Rituxan.
Incyte's Jakafi Demand Strong, Label Expansion to Boost Sales
by Zacks Equity Research
Incyte's (INCY) performance is likely to be strong due to rising demand of lead drug, Jakafi.
Novartis Presents Data on Multiple Sclerosis Drug Gilenya
by Zacks Equity Research
Novartis (NVS) announces encouraging data from a late-stage trial, ASSESS, on multiple sclerosis drug, Gilenya, which further reinforces its efficacy in treating relapses.
Novartis Presents Positive Data on Sickle Cell Disease Drug
by Zacks Equity Research
Novartis (NVS) announces positive results from a post hoc analysis of the phase II study, SUSTAIN, on pipeline candidate, crizanlizumab, being published in the American Journal of Hematology.
Roche (RHHBY) Presents Encouraging Data on MS Drug Ocrevus
by Zacks Equity Research
Roche's (RHHBY) MS drug Ocrevus lowers disability progression over five years in relapsing/primary progressive multiple sclerosis with an early initiation of treatment.
Novartis' Applications for MS Drug Accepted by FDA & EMA
by Zacks Equity Research
Novartis (NVS) progresses with its MS candidate, siponimod, as both the FDA and the EMA accepts the applications for the drug.
Roche's Hemlibra Receives FDA Approval for Label Expansion
by Zacks Equity Research
Roche (RHHBY) obtains the FDA approval for the label expansion of Hemlibra for the treatment of adults and children suffering haemophilia A without factor VIII inhibitors.
Roche (RHHBY) Presents Encouraging Data on SMA Drug Risdiplam
by Zacks Equity Research
Roche (RHHBY) reports encouraging data from two pivotal studies -- FIREFISH and SUNFISH -- on risdiplam for the treatment of Spinal Muscular Atrophy.
Eli Lilly's Ultra Rapid Lispro Succeeds in Diabetes Studies
by Zacks Equity Research
Eli Lilly's (LLY) insulin candidate, Ultra Rapid Lispro, meets primary endpoint of two late- stage studies in type I and type II diabetes patients of non-inferiorly to Humalog.
Novartis, Boston Pharma Ink Deal for 3 Anti-Infective Drugs
by Zacks Equity Research
Novartis inks licensing deal with Boston Pharma for the development of three novel anti-infective drug candidates.
Merck & Other Pharma Players Await FDA Decisions in October
by Kinjel Shah
FDA grants approval to 41 new treatments till the end of September.
Dr. Reddy's Sells Antibiotic Production Hub to UAE Drugmaker
by Zacks Equity Research
Dr. Reddy's (RDY) divests its Bristol, TN-based antibiotic manufacturing site and related assets to an Abu Dhabi-based company.
Here's Why Alynlam Pharmaceuticals is Hogging the Limelight
by Zacks Equity Research
Alnylam (ALNY) files an NDA for Onpattro in Japan and releases positive interim results for givosiran.
Roche Gets FDA Approval for New Formulation of Asthma Drug
by Zacks Equity Research
Roche (RHHBY) receives FDA approval for a dose prefilled syringe (PFS) formulation of its asthma drug, Xolair.
Eli Lilly (LLY) Gets FDA Nod for Migraine Drug Emgality
by Zacks Equity Research
Eli Lilly's (LLY) CGRP antibody Emgality injection gains an FDA approval for the preventive treatment of migraine in adults.
Pharma Stock Roundup: PFE, LLY Get Approval for New Drugs, Novartis to Cut Jobs
by Zacks Equity Research
FDA grants approval to Lilly's (LLY) Emgality for migraine and Pfizer's (PFE) Vizimpro for an advanced lung cancer indication. Novartis (NVS) to cut more than 2,000 jobs in Switzerland and U.K
Novartis to Cut Over 2000 Jobs, Focus on Higher Value Drugs
by Zacks Equity Research
Novartis (NVS) plans to lay off about 2000 jobs in Switzerland and the United Kingdom in order to focus on innovative, specialized and personalized medicines than on mass-produced products.
Mylan's Biosimilar of Neulasta Gets Positive CHMP Opinion
by Zacks Equity Research
Mylan (MYL) gets a positive CHMP opinion for Fulphila, a proposed biosimilar of Amgen's Neulasta.
Novartis Gets Positive CHMP Opinion for Drugs, Biosimilar
by Zacks Equity Research
Novartis (NVS) gets positive CHMP opinion for a label expansion of Gilenya, gene therapy, and a biosimilar of Neulasta.
Lilly's Migraine Drug Emgality Wins Positive CHMP Opinion
by Zacks Equity Research
Eli Lilly's (LLY) CGRP antibody Emgality gains a positive view from CHMP for the treatment of migraine in adults, who encounter minimum four migraine spells a month.